Kerri Fitzgerald

DocwireNews

Cabozantinib is approved to treat <a href="https://proddocwire.wpengine.com/abstracts/genomically-annotated-advanced-cohort/">patients with metastatic renal cell carcinoma</a> (RCC) based on studies conducted in those with clear-cell histology, but the activity of this treatment in patients with non-clear-cell RCC is poorly characterized. However, recent real-world research published in The Lancet Oncology supports the anti-tumor activity and safety of cabozantinib in patients with non-clear-cell RCC.The multicenter, international, retrospective, cohort study included 112 patients with <a href="https://proddocwire.wpengine.com/abstracts/hem-onc-abstracts/influence-obesity-renal-cell-carcinoma/">non-clear-cell RCC</a> who were treated at 22 participating centers (21 in the United States and one in Belgium). Eligible patients were those treated with oral cabozantinib during any treatment line between 2015 and 2018. Patients with mixed tumors with a clear-cell histology component were excluded.The researchers conducted a retrospective chart review to gather demographic, surgical, pathological, and systemic therapy data.In this cohort, 66 patients (59%) had papillary histology, 17 (15%) had Xp11.2 translocation histology, 15 (13%) had unclassified histology, 10 (9%) had chromophobe histology, and four (4%) had collecting duct histology.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Amazing work! <a href="https://twitter.com/DukeGUCancer?ref_src=twsrc%5Etfw">@DukeGUCancer</a> privileged to have been part of this nonclear cell RCC effort! Perfect timing of publication in <a href="https://twitter.com/hashtag/KidneyCancerAwarenessMonth?src=hash&amp;ref_src=twsrc%5Etfw">#KidneyCancerAwarenessMonth</a> <a href="https://t.co/boSxp5vwtV">https://t.co/boSxp5vwtV</a>
&mdash; Tian Zhang, MD, MHS (@TiansterZhang) <a href="https://twitter.com/TiansterZhang/status/1102893365409054726?ref_src=twsrc%5Etfw">March 5, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>Benefit observed with cabozantinib</h2>Across all histologies, 30 patients (27%) achieved an objective response (95% CI, 19-36), including one complete response and 29 partial responses. Fifty-three patients (47%) had stable disease.After a median follow-up of 11 months (interquartile range, 6-18 months), the median time to treatment failure was 6.7 months (95% CI, 5.5-8.6), the median progression-free survival was 7 months (95% CI, 5.7-9.0), and the median overall survival was 12 months (95% CI, 9.2-17.0).At the time of analysis, 38 patients remained on therapy. The median time to treatment failure was 6.7 months. At 6 months, 55% of patients were treatment failure free; at 12 months, 27% of patients were treatment failure free. Overall survival was 79% at 6 months and 51% at 12 months.The most common any-grade adverse events (AEs) were fatigue (n=58; 52%) and diarrhea (n=38; 34%). The most common grade 3 AEs were skin toxicity (rash and palmar-plantar erythrodysesthesia; n=5; 4%) and hypertension (n=4; 4%). No treatment-related deaths occurred.<h2>Benefits remain across different mutation types</h2>Fifty-four patients had next-generation sequencing data available, and the most frequently altered somatic genes were CDKN2A (n=12; 22%) and MET (n=11; 20%). Response to treatment occurred across different mutation types.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Powerful collaborative work from <a href="https://twitter.com/neerajaiims?ref_src=twsrc%5Etfw">@neerajaiims</a> and colleagues! <a href="https://twitter.com/huntsmancancer?ref_src=twsrc%5Etfw">@huntsmancancer</a> <a href="https://t.co/3UaS4KrLL1">https://t.co/3UaS4KrLL1</a>
&mdash; Neli Ulrich, PhD (@NeliMUlrich) <a href="https://twitter.com/NeliMUlrich/status/1102812947397500928?ref_src=twsrc%5Etfw">March 5, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Cabozantinib May be an Option for Advanced Non-Clear-Cell Renal Cell Carcinoma

Oncology

Cabozantinib is approved to treat patients with metastatic renal cell carcinoma (RCC) based on studies conducted in those with clear-cell histology, but the activity of this ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe